Progyny (PGNY) stock fell 6% as Q3 sales guidance missed expectations, despite Q2 results beating Wall Street estimates.
Progyny (NASDAQ: PGNY), a fertility benefits management company, saw its shares fall 6% on Friday after the company reported second-quarter results showing a 5% increase in sales (or 11% excluding the loss of a major client last year) and a 15% increase in adjusted earnings per share, both exceeding Wall Street expectations. However, management's guidance for third-quarter sales growth of only 7% to 11%, along with an anticipated slight sequential decline in earnings, triggered a negative market reaction.
No AI analysis yet. Tap the "AI Analysis" button above to generate one now.
Source:Yahoo财经 · Source Link
Disclaimer: This content reflects only the author’s personal views and does not constitute any investment or financial advice. If you discover any content that violates regulations,Click to Report
24H Trending
-
1
XRP is testing the $1.50 resistance level, a key threshold that has capped its advances for roughly 230 days, with a break potentially leading to $1.80+
-
2
Seoul stocks rise 1.65% on chip gains despite Middle East tensions
-
3
Binance Stock Trading Platform Adds 25 New Stocks
-
4
Central Bank Digital Currency (CBDC) In-Depth Analysis: Global Progress and Impact
-
5
OKX App Download Guide: Get the World's Leading Cryptocurrency Trading Platform Application
-
6
US equity futures rise, led by AI stocks; oil prices fall over 2% to around $101; US Treasury yields decline; US and Chinese officials discuss AI national security "notification mechanism."
-
7
BiblePay (BBP) Cryptocurrency Analysis: Charitable Mission, Technical Features, and Market Status
-
8
Gamium (GMM) Token Analysis: Value, Ecosystem, and Investment Risk Assessment
-
9
Commodities trader Trafigura plans to float its supertanker arm Volare Shipping in Oslo, marking the business's first IPO
-
10
Morgan Stanley’s Wilson Says US Stocks Risk 7% Drop in Near Term
Markets Today
Recommended Reading






